Genentech’s TECENTRIQ in Combination with Chemotherapy Helped People with Previously-Untreated
Extensive-Stage Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy
– IMpower133 is the first Phase III study with an immunotherapy-based combination to show improvement in
overall survival and progression-free survival in the initial treatment of extensive-stage small cell lung cancer (ES-SCLC)
–
– There has been limited treatment progress for people with ES-SCLC in the past 20 years –
– Data will be submitted to health authorities globally, including the U.S. Food and Drug Administration
(FDA) and European Medicines Agency (EMA) –
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower133 study met its
co-primary endpoints of overall survival (OS) and progression-free survival (PFS) at its first interim analysis. The study
demonstrated that initial (first-line) treatment with the combination of TECENTRIQ® (atezolizumab) plus chemotherapy
(carboplatin and etoposide) helped people with extensive-stage small cell lung cancer (ES-SCLC) live significantly longer compared
to chemotherapy alone. The TECENTRIQ-based combination also reduced the risk of disease worsening or death (PFS) compared to
chemotherapy alone. Safety for the TECENTRIQ and chemotherapy combination appeared consistent with the known safety profile of the
individual medicines, and no new safety signals were identified with the combination. These data will be presented at an upcoming
medical meeting.
“These are the first positive Phase III survival results for any immunotherapy-based combination in the initial treatment of
extensive-stage small cell lung cancer, a particularly difficult-to-treat type of disease,” said Sandra Horning, M.D., chief
medical officer and head of Global Product Development. “The clinically meaningful results from the IMpower133 study add to the
growing body of evidence demonstrating that TECENTRIQ-based combinations may be an effective treatment for different types of
advanced lung cancer. We look forward to working with health authorities globally to bring this potential treatment option to
people with this type of disease as soon as possible.”
This is the fourth positive Phase III lung cancer study evaluating a TECENTRIQ-based combination to read out this year and the
fifth positive study overall. Currently, Genentech has eight Phase III lung cancer studies underway evaluating TECENTRIQ alone or
in combination with other medicines across different types of lung cancer.
About the IMpower133 study
IMpower133 is a Phase III, multicenter, double-blinded, randomized placebo-controlled study evaluating the efficacy and safety
of TECENTRIQ in combination with carboplatin and etoposide versus chemotherapy (carboplatin plus etoposide) alone in
chemotherapy-naïve people with ES-SCLC. The study enrolled 403 people who were randomized equally (1:1) to receive:
- TECENTRIQ in combination with carboplatin and etoposide (Arm A), or
- Placebo in combination with carboplatin and etoposide (Arm B, control arm)
During the treatment-induction phase, people received treatment on 21-day cycles for four cycles, followed by maintenance with
TECENTRIQ or placebo until progressive disease (PD) as assessed by the investigator using Response Evaluation Criteria in Solid
Tumors Version 1.1 (RECIST v1.1). Treatment could be continued until persistent radiographic PD or symptomatic deterioration was
observed.
The co-primary endpoints were:
- PFS as determined by the investigator using RECIST v1.1 in the intention-to-treat (ITT)
population
- OS in the ITT population
IMpower133 met its OS and PFS co-primary endpoints as per the study protocol.
About lung cancer
According to the American Cancer Society, it is estimated that more than 234,000 Americans will be diagnosed with lung cancer in
2018, and SCLC accounts for approximately 15 percent of all lung cancers. It is estimated that approximately 60 percent of lung
cancer diagnoses in the United States are made when the disease is in the advanced stages.
About TECENTRIQ ® (atezolizumab)
TECENTRIQ is a monoclonal antibody designed to bind with a protein called PD-L1. TECENTRIQ is designed to bind to PD-L1
expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By
inhibiting PD-L1, TECENTRIQ may enable the re-activation of T cells. TECENTRIQ may also affect normal cells.
TECENTRIQ U.S. Indication (pronounced ‘tē-SEN-trik’)
TECENTRIQ is a prescription medicine used to treat:
A type of bladder and urinary tract cancer called urothelial carcinoma.
- TECENTRIQ may be used when your bladder cancer:
- has spread or cannot be removed by surgery, and if you have any one of the following
conditions:
- you are not able to take chemotherapy that contains a medicine called cisplatin, and your doctor
has tested your cancer and found high levels of a specific protein on your cancer called programmed death-ligand 1 (PD-L1),
or
- you are not able to take chemotherapy that contains any platinum regardless of the levels of
PD-L1 on your cancer, or
- you have tried chemotherapy that contains platinum, and it did not work or is no longer
working
The approval of TECENTRIQ in these patients is based on a study that measured response rate and duration of response. There
is an ongoing study to confirm clinical benefit.
A type of lung cancer called non-small cell lung cancer (NSCLC).
-
TECENTRIQ may be used when your lung cancer:
- has spread or grown, and
- you have tried chemotherapy that contains platinum, and it did not work or is no longer
working
If your tumor has an abnormal EGFR or ALK gene, you should have also tried an FDA-approved therapy for tumors with these
abnormal genes, and it did not work or is no longer working.
It is not known if TECENTRIQ is safe and effective in children.
Important Safety Information
What is the most important information about TECENTRIQ?
TECENTRIQ can cause the immune system to attack normal organs and tissues and can affect the way they work. These problems can
sometimes become serious or life threatening and can lead to death.
Patients should call or see their healthcare provider right away if they get any symptoms of the following problems or these
symptoms get worse.
TECENTRIQ can cause serious side effects, including:
- Lung problems (pneumonitis)–signs and symptoms may include new or worsening cough, shortness
of breath, and chest pain
- Liver problems (hepatitis)–signs and symptoms of hepatitis may include yellowing of the skin
or the whites of the eyes, severe nausea or vomiting, pain on the right side of the stomach area (abdomen), drowsiness, dark
urine (tea colored), bleeding or bruising more easily than normal, and feeling less hungry than usual
- Intestinal problems (colitis)–signs and symptoms of colitis may include diarrhea (loose
stools) or more bowel movements than usual, blood or mucous in the stools or dark, tarry, sticky stools, and severe stomach area
(abdomen) pain or tenderness
- Hormone gland problems (especially the thyroid, adrenal glands, pancreas, and pituitary)–signs
and symptoms that the hormone glands are not working properly may include headaches that will not go away or unusual headaches,
extreme tiredness, weight gain or weight loss, dizziness or fainting, feeling more hungry or thirsty than usual, hair loss,
changes in mood or behavior (such as decreased sex drive, irritability, or forgetfulness), feeling cold, constipation, the voice
gets deeper, urinating more often than usual, nausea or vomiting, and stomach area (abdomen) pain
- Problems in other organs–signs and symptoms may include severe muscle weakness, numbness or
tingling in hands or feet, confusion, blurry vision, double vision, or other vision problems, changes in mood or behavior,
extreme sensitivity to light, neck stiffness, eye pain or redness, skin blisters or peeling, chest pain, irregular heartbeat,
shortness of breath, or swelling of the ankles
- Severe infections–signs and symptoms of infection may include fever, cough, flu-like symptoms,
pain when urinating, and frequent urination or back pain
- Severe infusion reactions–signs and symptoms of infusion reactions may include chills or
shaking, itching or rash, flushing, shortness of breath or wheezing, swelling of the face or lips, dizziness, fever, feeling like
passing out, and back or neck pain
Getting medical treatment right away may help keep these problems from becoming more serious. A healthcare provider may
treat patients with corticosteroid or hormone replacement medicines. A healthcare provider may delay or completely stop treatment
with TECENTRIQ if patients have severe side effects.
Before receiving TECENTRIQ, patients should tell their healthcare provider about all of their medical conditions, including
if they:
- have immune system problems (such as Crohn’s disease, ulcerative colitis, or lupus); have had an
organ transplant; have lung or breathing problems; have liver problems; have a condition that affects the nervous system (such as
myasthenia gravis or Guillain-Barre syndrome); or are being treated for an infection
- are pregnant or plan to become pregnant. TECENTRIQ can harm an unborn baby. Patients should tell
their healthcare provider right away if they become pregnant or think they may be pregnant during treatment with TECENTRIQ. If
patients are able to become pregnant:
- A healthcare provider should do a pregnancy test before they start treatment with TECENTRIQ.
- They should use an effective method of birth control during their treatment and for at least 5
months after the last dose of TECENTRIQ.
- are breastfeeding or plan to breastfeed. It is not known if TECENTRIQ passes into the breast milk. Do
not breastfeed during treatment and for at least 5 months after the last dose of TECENTRIQ
Patients should tell their healthcare provider about all the medicines they take, including prescription and
over-the-counter medicines, vitamins, and herbal supplements.
The most common side effects of TECENTRIQ in people with urothelial carcinoma include:
- feeling tired
- decreased appetite
- nausea
- constipation
- urinary tract infection
- diarrhea
- fever
The most common side effects of TECENTRIQ in people with non-small cell lung cancer include:
- feeling tired
- decreased appetite
- muscle pain
- cough
- shortness of breath
TECENTRIQ may cause fertility problems in females, which may affect the ability to have children. Patients should talk to their
healthcare provider if they have concerns about fertility.
These are not all the possible side effects of TECENTRIQ. Patients should ask their healthcare provider or pharmacist for more
information. Patients should call their doctor for medical advice about side effects.
Report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch . Report side effects to Genentech at 1-888-835-2555.
Please visit http://www.Tecentriq.com for the TECENTRIQ full Prescribing Information for additional Important Safety
Information.
About Genentech in Personalized Cancer Immunotherapy
For more than 30 years, Genentech has been developing medicines with the goal to redefine treatment in oncology. Today, we’re
investing more than ever to bring personalized cancer immunotherapy (PCI) to people with cancer. The goal of PCI is to provide each
person with a treatment tailored to harness his or her own immune system to fight cancer. Genentech is studying more than 20
investigational medicines, 10 of which are in clinical trials. In every study we are evaluating biomarkers to identify which people
may be appropriate candidates for our medicines. For more information visit http://www.gene.com/cancer-immunotherapy.
About Genentech in Lung Cancer
Lung cancer is a major area of focus and investment for Genentech, and we are committed to developing new approaches, medicines
and tests that can help people with this deadly disease. Our goal is to provide an effective treatment option for every person
diagnosed with lung cancer. We currently have four approved medicines to treat certain kinds of lung cancer and more than 10
medicines being developed to target the most common genetic drivers of lung cancer or to boost the immune system to combat the
disease.
About Genentech
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and
commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche
Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.
Genentech
Media Contact:
Meghan Cox, 650-467-6800
or
Advocacy Contact:
Angela Wilson, 919-244-7758
or
Investor Contacts:
Loren Kalm, 650-225-3217
Karl Mahler, 011 41 61 687 8503
View source version on businesswire.com: https://www.businesswire.com/news/home/20180624005074/en/